NASDAQ:IKT
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. reported net income of −$48.3M in fiscal 2025. Free cash flow was −$27.8M, and the diluted share count rose 314.6%.Summary generated from Inhibikase Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−36.0%
Debt / equityn/a
Free cash flow−$27.8M
FCF marginn/a
Share count change+314.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 | 0 | 0 | 0 | n/a |
| Operating income | −15 | −18 | −20 | −29 | −52 |
| Net income | −15 | −18 | −19 | −28 | −48 |
| Free cash flow | −14 | −18 | −18 | −19 | −28 |
Recent filings
- 8-KRegulation FD disclosure
Sep 8, 2026 - 8-KChange in auditor
Aug 26, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 4Insider transaction report
Jul 31, 2026 - 4Insider transaction report
Jul 31, 2026 - 8-KCurrent report
Jul 29, 2026 - 8-KRegulation FD disclosure
Jul 23, 2026